Trial Profile
Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2019
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Bursitis; Inflammation; Plantar fasciitis; Tennis elbow
- Focus Therapeutic Use
- 06 Oct 2019 Status changed from recruiting to discontinued.
- 02 Mar 2015 New trial record